Tovinontrine
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585441

CAS#: 2062661-53-2

Description: Tovinontrine, also known as IMR-687, is a phosphodiesterase 9 (PDE9) inhibitor. IMR-687 increased cGMP and HbF in erythroid K562 and UT-7 cells and increased the percentage of HbF positive erythroid cells generated in vitro using a two-phase liquid culture of CD34+ progenitors from sickle cell blood or bone marrow. Oral daily dosing of IMR-687 in the Townes transgenic mouse SCD model, increased HbF and reduced red blood cell sickling, immune cell activation and microvascular stasis.

Chemical Structure

img
Tovinontrine
CAS# 2062661-53-2
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 585441
Name: Tovinontrine
CAS#: 2062661-53-2
Chemical Formula: C21H26N6O2
Exact Mass: 394.21
Molecular Weight: 394.480
Elemental Analysis: C, 63.94; H, 6.64; N, 21.30; O, 8.11

Price and Availability

Size Price Availability Quantity
1mg USD 90 Ready to ship
5mg USD 350 Ready to ship
10mg USD 550 Ready to ship
25mg USD 1150 Ready to ship
50mg USD 1750 Ready to ship
100mg USD 2650 Ready to ship
200mg USD 3650 Ready to ship
Bulk inquiry

Synonym: Tovinontrine; IMR-687; IMR 687; IMR687;

IUPAC/Chemical Name: 6-{(3S,4S)-4-methyl-1-[(pyrimidin-2-yl)methyl]pyrrolidin-3-yl}-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one

InChi Key: GWGNPYYVGANHRJ-GDBMZVCRSA-N

InChi Code: InChI=1S/C21H26N6O2/c1-14-10-26(13-19-22-5-2-6-23-19)11-16(14)17-12-27-18(21(28)25-17)9-24-20(27)15-3-7-29-8-4-15/h2,5-6,9,12,14-16H,3-4,7-8,10-11,13H2,1H3,(H,25,28)/t14-,16-/m1/s1

SMILES Code: O=C1C2=CN=C(C3CCOCC3)N2C=C([C@@H]4CN(CC5=NC=CC=N5)C[C@H]4C)N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Tovinontrine is a PDE9 inhibitor; IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively.
In vitro activity: To be determined
In vivo activity: Tovinontrine specifically targets phosphodiesterase-9, leading to increased cellular cGMP levels and HbF production. In preclinical studies, tovinontrine demonstrated its efficacy in reducing red blood cell sickling, immune cell activation, and microvascular stasis in a mouse SCD model. Tovinontrine showed no central nervous system accumulation, genotoxicity, myelotoxicity, or adverse effects on fertility and fetal development. Reference: Haematologica. 2020 Mar;105(3):623-631. https://pubmed.ncbi.nlm.nih.gov/31147439/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 100.0 253.50

Preparing Stock Solutions

The following data is based on the product molecular weight 394.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. McArthur JG, Svenstrup N, Chen C, Fricot A, Carvalho C, Nguyen J, Nguyen P, Parachikova A, Abdulla F, Vercellotti GM, Hermine O, Edwards D, Ribeil JA, Belcher JD, Maciel TT. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar;105(3):623-631. doi: 10.3324/haematol.2018.213462. Epub 2019 May 30. PMID: 31147439; PMCID: PMC7049346.
In vitro protocol: To be determined
In vivo protocol: 1. McArthur JG, Svenstrup N, Chen C, Fricot A, Carvalho C, Nguyen J, Nguyen P, Parachikova A, Abdulla F, Vercellotti GM, Hermine O, Edwards D, Ribeil JA, Belcher JD, Maciel TT. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar;105(3):623-631. doi: 10.3324/haematol.2018.213462. Epub 2019 May 30. PMID: 31147439; PMCID: PMC7049346.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Langer AL, Esrick EB. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):600-606. doi: 10.1182/hematology.2021000313. PMID: 34889443.


2: Makis A, Voskaridou E, Papassotiriou I, Hatzimichael E. Novel Therapeutic Advances in β-Thalassemia. Biology (Basel). 2021 Jun 18;10(6):546. doi: 10.3390/biology10060546. PMID: 34207028; PMCID: PMC8235056.


3: McArthur JG, Svenstrup N, Chen C, Fricot A, Carvalho C, Nguyen J, Nguyen P, Parachikova A, Abdulla F, Vercellotti GM, Hermine O, Edwards D, Ribeil JA, Belcher JD, Maciel TT. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar;105(3):623-631. doi: 10.3324/haematol.2018.213462. Epub 2019 May 30. PMID: 31147439; PMCID: PMC7049346.